References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30. doi:https://doi.org/10.3322/caac.21590.
- Issa IA, Noureddine M. Colorectal cancer screening: an updated review of the available options. World J Gastroenterol. 2017;23(28):5086–96. doi:https://doi.org/10.3748/wjg.v23.i28.5086.
- Bressler B, Paszat LF, Chen Z, Rothwell DM, Vinden C, Rabeneck L. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. Gastroenterology. 2007;132(1):96–102. doi:https://doi.org/10.1053/j.gastro.2006.10.027.
- Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89–103. doi:https://doi.org/10.5114/pg.2018.81072.
- Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926–30. doi:https://doi.org/10.1126/science.aar3247.
- Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223–38. doi:https://doi.org/10.1038/nrc.2017.7.
- Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. doi:https://doi.org/10.1126/scitranslmed.3007094.
- Nguyen HT, Tran DH, Ngo QD, Pham HT, Tran TT, Tran VU, et al. Evaluation of a liquid biopsy protocol using ultra-deep massive parallel sequencing for detecting and quantifying circulation tumor DNA in colorectal cancer patients. Cancer Invest. 2020;38(2):85–93. doi:https://doi.org/10.1080/07357907.2020.1713350.
- Tran LS, Nguyen Q-TT, Nguyen CV, Tran V-U, Nguyen T-HT, Le HT, et al. Ultra-deep massive parallel sequencing of plasma cell-free dna enables large-scale profiling of driver mutations in Vietnamese patients with advanced non-small cell lung cancer. Front Oncol. 2020;10(1351):1351. doi:https://doi.org/10.3389/fonc.2020.01351.
- Ma F, Guan Y, Yi Z, Chang L, Li Q, Chen S, et al. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. Int J Cancer. 2020;146(5):1359–68. doi:https://doi.org/10.1002/ijc.32536.
- Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic – implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297–312. doi:https://doi.org/10.1038/s41571-020-00457-x.
- Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9(403):2,7,8, 10. doi:https://doi.org/10.1126/scitranslmed.aan2415.
- Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446–51. doi:https://doi.org/10.1038/nature22364.
- Strom SP. Current practices and guidelines for clinical next-generation sequencing oncology testing. Cancer Biol Med. 2016;13(1):3–11.
- Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570(7761):385–9. doi:https://doi.org/10.1038/s41586-019-1272-6.
- Razavi P, Li BT, Brown DN, Jung B, Hubbell E, Shen R, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;25(12):1928–37. doi:https://doi.org/10.1038/s41591-019-0652-7.
- Ma M, Zhu H, Zhang C, Sun X, Gao X, Chen G. Liquid biopsy"-ctDNA detection with great potential and challenges. Ann Transl Med. 2015;3(16):235.
- Fiala C, Diamandis EP. Mutations in normal tissues-some diagnostic and clinical implications. BMC Med. 2020;18(1):283. doi:https://doi.org/10.1186/s12916-020-01763-y.
- Tian G, Xia L, Li Z, Li X, Xu F, Liu C, He J. Baseline mutation profiling of circulating cell-free DNA from healthy individuals to improve the detection accuracy of circulating tumor DNA in cancers. JCO. 2017;35(15_suppl):e23057–e23057. doi:https://doi.org/10.1200/JCO.2017.35.15_suppl.e23057.
- Smith T, Heger A, Sudbery I. UMI-tools: modeling sequencing errors in unique molecular identifiers to improve quantification accuracy. Genome Res. 2017;27(3):491–9. doi:https://doi.org/10.1101/gr.209601.116.
- Chen W, Li Y, Easton J, Finkelstein D, Wu G, Chen X. UMI-count modeling and differential expression analysis for single-cell RNA sequencing. Genome Biol. 2018;19(1):70. doi:https://doi.org/10.1186/s13059-018-1438-9.
- Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004;91(2):355–8. doi:https://doi.org/10.1038/sj.bjc.6601894.
- Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114–20. doi:https://doi.org/10.1093/bioinformatics/btu170.
- Li H, Durbin R. Fast and accurate long-read alignment with burrows-wheeler transform. Bioinformatics. 2010;26(5):589–95. doi:https://doi.org/10.1093/bioinformatics/btp698.
- https://github.com/fulcrumgenomics/fgbio. 2019. [updated 2019; cited 2021 5th July 2021].
- https://github.com/fulcrumgenomics/fgbio/blob/master/src/main/scala/com/fulcrumgenomics/umi/CallMolecularConsensusReads.scala. 2019. [updated 2019; cited 2021 5th July 2021].
- Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R, et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 2016;44(11):e108. doi:https://doi.org/10.1093/nar/gkw227.
- McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al. The ensembl variant effect predictor. Genome Biol. 2016;17(1):122. doi:https://doi.org/10.1186/s13059-016-0974-4.
- Boettcher S, Ebert BL. Clonal hematopoiesis of indeterminate potential. J Clin Oncol. 2019;37(5):419–22. doi:https://doi.org/10.1200/JCO.2018.79.3588.
- Liu J, Chen X, Wang J, Zhou S, Wang CL, Ye MZ, et al. Biological background of the genomic variations of cf-DNA in healthy individuals. Ann Oncol. 2019;30(3):464–70. doi:https://doi.org/10.1093/annonc/mdy513.
- Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745–59. doi:https://doi.org/10.1016/j.annonc.2020.02.011.
- Landrum MJ, Chitipiralla S, Brown GR, Chen C, Gu B, Hart J, et al. ClinVar: improvements to accessing data. Nucleic Acids Res. 2020;48(D1):D835–d44. doi:https://doi.org/10.1093/nar/gkz972.
- Rossi G, Ignatiadis M. Promises and pitfalls of using liquid biopsy for precision medicine. Cancer Res. 2019;79(11):2798–804. doi:https://doi.org/10.1158/0008-5472.CAN-18-3402.
- Pham T, Bui L, Kim G, Hoang D, Tran T, Hoang M. Cancers in Vietnam-Burden and control efforts: a narrative scoping review. Cancer Control. 2019;26(1):1073274819863802. doi:https://doi.org/10.1177/1073274819863802.
- Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4. doi:https://doi.org/10.1245/s10434-010-0985-4.
- Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4(136):136ra68.
- Chan HT, Nagayama S, Chin YM, Otaki M, Hayashi R, Kiyotani K, et al. Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy. Mol Oncol. 2020;14(8):1719–30. doi:https://doi.org/10.1002/1878-0261.12727.
- Chiou SH, Sheu BC, Chang WC, Huang SC, Hong-Nerng H. Current concepts of tumor-infiltrating lymphocytes in human malignancies. J Reprod Immunol. 2005;67(1–2):35–50. doi:https://doi.org/10.1016/j.jri.2005.06.002.
- Sharma Y, Miladi M, Dukare S, Boulay K, Caudron-Herger M, Groß M, et al. A pan-cancer analysis of synonymous mutations. Nat Commun. 2019;10(1):2569. doi:https://doi.org/10.1038/s41467-019-10489-2.
- Tran LS, Pham HT, Tran VU, Tran TT, Dang AH, Le DT, et al. Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients. PLOS One. 2019;14(12):e0226193. doi:https://doi.org/10.1371/journal.pone.0226193.
- Wu H-T, Kalashnikova E, Mehta S, Salari R, Sethi H, Zimmermann B, et al. Characterization of clonal hematopoiesis of indeterminate potential mutations from germline whole exome sequencing data. JCO. 2020;38(15_suppl):1525. doi:https://doi.org/10.1200/JCO.2020.38.15_suppl.1525.
- Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019;366(6465):eaan4673. doi:https://doi.org/10.1126/science.aan4673.
- Gormally E, Vineis P, Matullo G, Veglia F, Caboux E, Le Roux E, et al. TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res. 2006;66(13):6871–6. doi:https://doi.org/10.1158/0008-5472.CAN-05-4556.